- Home
- ZDGE vs KPTI Comparison
ZDGE vs KPTI Comparison
Compare ZDGE & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZDGE
- KPTI
- Stock Information
- Founded
- ZDGE 2008
- KPTI 2008
- Country
- ZDGE United States
- KPTI United States
- Employees
- ZDGE N/A
- KPTI N/A
- Industry
- ZDGE Computer Software: Prepackaged Software
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- ZDGE Technology
- KPTI Health Care
- Exchange
- ZDGE Nasdaq
- KPTI Nasdaq
- Market Cap
- ZDGE 39.9M
- KPTI 44.5M
- IPO Year
- ZDGE N/A
- KPTI 2013
- Fundamental
- Price
- ZDGE $3.25
- KPTI $6.26
- Analyst Decision
- ZDGE
- KPTI Buy
- Analyst Count
- ZDGE 0
- KPTI 6
- Target Price
- ZDGE N/A
- KPTI $39.80
- AVG Volume (30 Days)
- ZDGE 41.8K
- KPTI 106.2K
- Earning Date
- ZDGE 10-28-2025
- KPTI 11-04-2025
- Dividend Yield
- ZDGE N/A
- KPTI N/A
- EPS Growth
- ZDGE N/A
- KPTI N/A
- EPS
- ZDGE N/A
- KPTI N/A
- Revenue
- ZDGE $29,511,000.00
- KPTI $137,269,000.00
- Revenue This Year
- ZDGE N/A
- KPTI $3.67
- Revenue Next Year
- ZDGE $2.95
- KPTI $9.40
- P/E Ratio
- ZDGE N/A
- KPTI N/A
- Revenue Growth
- ZDGE 1.27
- KPTI N/A
- 52 Week Low
- ZDGE $1.73
- KPTI $3.51
- 52 Week High
- ZDGE $4.89
- KPTI $16.95
- Technical
- Relative Strength Index (RSI)
- ZDGE 51.51
- KPTI 52.25
- Support Level
- ZDGE $2.91
- KPTI $5.70
- Resistance Level
- ZDGE $3.25
- KPTI $6.85
- Average True Range (ATR)
- ZDGE 0.17
- KPTI 0.61
- MACD
- ZDGE 0.05
- KPTI -0.14
- Stochastic Oscillator
- ZDGE 67.26
- KPTI 22.86
About ZDGE Zedge Inc. Class B
Zedge Inc provides content distribution platforms. Its content platform enables consumers to personalize their mobile devices with free, high-quality ringtones, wallpapers, home screen app icons, widgets and notification sounds as well as paint, a generative AI wallpaper maker, GuruShots, a skill-based photo challenge game, and Emojipedia. The company also launched a Zedge app. It has two reportable segments, which are the Zedge Marketplace and GuruShots.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.